trending Market Intelligence /marketintelligence/en/news-insights/trending/B_ncEUhzAxNnf3YxTFxNPg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Medicenna raises C$6.9M via public offering of units

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Medicenna raises C$6.9M via public offering of units

Medicenna Therapeutics Corp. raised about C$6.9 million in gross proceeds via a public offering to fund the development of its cancer drugs.

The Toronto-based company sold 5,307,693 units at C$1.30 apiece, inclusive of the 692,307 units the offering's underwriters acquired as part of their overallotment option.

Bloom Burton Securities Inc. was the lead agent for the offering while Mackie Research Capital Corp. and Haywood Securities Inc. acted as agents.

Medicenna plans to use the proceeds to advance its cancer treatments MDNA55 and MDNA19. The company will also use part of the proceeds for working capital and general corporate purposes.